Targets › MAPK14
1 program from 1 company in 2 trials: 2 Phase 2; Neurology.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. (UniProt, Q16539)
Open in Phaseline: the race on MAPK14, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| EIP Pharma | Neflamapimod MAP kinase p38 alpha inhibitor | MAPK14 | Phase 2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA); Moderate to Severe Acute Ischaemic Stroke | – |
Nonfluent Variant Primary Progressive Aphasia (nfvPPA) (1) Moderate to Severe Acute Ischaemic Stroke (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.